NovaBridge Biosciences (NBP) Stock Overview

A biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. More details

NBP fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 55.3% below our estimate of its fair value

Analysts in good agreement that stock price will rise by 101.9%

Risk Analysis

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months compared to the US market

Shareholders have been substantially diluted in the past year

Earnings are forecast to decline by an average of 7.5% per year for the next 3 years

+ 1 more risk

NBP Community Fair Values

Create Narrative

See what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

NovaBridge Biosciences Competitors

Price History & Performance

Summary of share price highs, lows and changes for NovaBridge Biosciences
Historical stock prices
Current Share Price	US$4.26
52 Week High	US$6.79
52 Week Low	US$0.59
Beta	1.62
1 Month Change	-2.07%
3 Month Change	21.37%
1 Year Change	290.83%
3 Year Change	18.01%
5 Year Change	-87.79%
Change since IPO	-65.92%

Recent updates

I-Mab Biopharma Stock: Caution Warranted After Huge Surge

Oct 14

I-Mab: Trading Below Net Cash With Multiple Upside Options

Feb 18

We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate

Feb 08

I-Mab: Another CD47 Inhibitor Biotech With Great Potential

Sep 27

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

Sep 13

I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M

Aug 30

I-Mab and senior executives may buy $40M worth of shares; stock up 10%

Aug 23

Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts

Aug 20

I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China

Jul 22

I-Mab Valuation Offers A Biotech Investment Opportunity

Jun 23

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth

May 24

I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat

May 06

Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates

Apr 01

I-Mab Founder Retakes Reins In Latest Shakeup Ahead Of Commercialization Phase

Jan 03

I-Mab Gets Boost From Latest Industry Signals On New Cancer Treatment

Oct 14

Shareholder Returns

	NBP	US Biotechs	US Market
7D	-8.0%	1.6%	-1.6%
1Y	290.8%	1.0%	14.4%

Return vs Industry: NBP exceeded the US Biotechs industry which returned -0.6% over the past year.

Return vs Market: NBP exceeded the US Market which returned 17.2% over the past year.

Price Volatility

Is NBP's price volatile compared to industry and market?
NBP volatility
NBP Average Weekly Movement	17.5%
Biotechs Industry Average Movement	10.9%
Market Average Movement	6.5%
10% most volatile stocks in US Market	17.2%
10% least volatile stocks in US Market	3.0%

Stable Share Price: NBP's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: NBP's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2014	32	Sean Fu	www.i-mabbiopharma.com

NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor.

NovaBridge Biosciences Fundamentals Summary

How do NovaBridge Biosciences's earnings and revenue compare to its market cap?
NBP fundamental statistics
Market cap	US$492.19m
Earnings (TTM)	-US$39.99m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-12.3x

P/E Ratio

Is NBP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NBP income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$39.99m
Earnings	-US$39.99m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.35
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did NBP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/05 00:00
End of Day Share Price	2025/11/05 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NovaBridge Biosciences is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Bo Li	BofA Global Research
Kumaraguru Raja	Brookline Capital Markets
Justin Zelin	BTIG

NovaBridge Biosciences (NBP) Stock Overview

Rewards

Risk Analysis

NovaBridge Biosciences Competitors

Bicycle Therapeutics

Prothena

Rigel Pharmaceuticals

XOMA Royalty

Price History & Performance

Recent News & Updates

Novabridge Biosciences Appoints Ian Woo to Its Board of Directors

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

I-Mab Biopharma Stock: Caution Warranted After Huge Surge

I-Mab Announces Acceleration of Givastomig Investment

I-Mab Announces Board Changes

I-Mab Completes Enrollment in Planned Phase 1B Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers

Recent updates

Novabridge Biosciences Appoints Ian Woo to Its Board of Directors

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

I-Mab Biopharma Stock: Caution Warranted After Huge Surge

I-Mab Announces Acceleration of Givastomig Investment

I-Mab Announces Board Changes

I-Mab Completes Enrollment in Planned Phase 1B Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers

I-Mab has completed a Follow-on Equity Offering in the amount of $65.000001 million.

I-Mab Inc. Announces Data Based on the Results of the Dose Escalation Part of A Phase 1B Study Evaluating the Givastomig Combination as First Line Therapy

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers At Esmo Gi 2025

I-Mab to Report Q1, 2025 Results on May 15, 2025

I-Mab Announces Accelerated Givastomig Phase 1B Study Progress

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

I-Mab Appoints Sean (Xi-Yong) Fu as Chief Executive Officer

I-Mab to Report Q3, 2024 Results on Nov 14, 2024

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

I-Mab to Report First Half, 2024 Results on Aug 28, 2024

I-Mab Announces Board and Committee Changes

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to CN¥12.72 loss

I-Mab: Trading Below Net Cash With Multiple Upside Options

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-Mab Announces Board Changes , Effective February 10, 2024

Member of Scientific Advisory Board notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Price target decreased by 17% to US$21.56

Chief Legal Officer notifies of intention to sell stock

I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy (PMN)

I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503

New minor risk - Share price stability

Consensus revenue estimates fall by 15%

Consensus revenue estimates fall by 78%

Price target decreased by 19% to US$24.47

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab to Report First Half, 2023 Results on Aug 17, 2023

Member of Scientific Advisory Board notifies of intention to sell stock

I-Mab Announces the Appointment of Raj Kannan as Member of the Board of Directors

TRACON Pharmaceuticals, Inc. Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma

Price target increased by 8.5% to US$27.65

Interim CFO notifies of intention to sell stock

Price target increased by 7.2% to US$27.30

Price target decreased by 11% to US$29.81

Price target decreased by 7.7% to US$33.57

We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate

Member of Scientific Advisory Board notifies of intention to sell stock

Price target decreased to US$36.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues miss analyst expectations

I-Mab: Another CD47 Inhibitor Biotech With Great Potential

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

Consensus revenue estimates fall by 63%

I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M

I-Mab and senior executives may buy $40M worth of shares; stock up 10%

Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts

Consensus revenue estimates fall by 13%

Price target decreased to US$58.94

I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China

I-Mab Valuation Offers A Biotech Investment Opportunity

Price target decreased to US$74.89

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth